AbbVie Pre-Tax Income 2010-2024 | ABBV
AbbVie annual/quarterly pre-tax income history and growth rate from 2010 to 2024. Pre-tax income can be defined as company's earnings or loss before taxes on income have been accounted for.
- AbbVie pre-tax income for the quarter ending December 31, 2024 was $-2.269B, a 287.21% decline year-over-year.
- AbbVie pre-tax income for the twelve months ending December 31, 2024 was $3.716B, a 40.54% decline year-over-year.
- AbbVie annual pre-tax income for 2024 was $3.716B, a 40.54% decline from 2023.
- AbbVie annual pre-tax income for 2023 was $6.25B, a 53.62% decline from 2022.
- AbbVie annual pre-tax income for 2022 was $13.477B, a 3.76% increase from 2021.
AbbVie Annual Pre-Tax Income
(Millions of US $) |
| 2024 |
$3,716 |
| 2023 |
$6,250 |
| 2022 |
$13,477 |
| 2021 |
$12,989 |
| 2020 |
$3,398 |
| 2019 |
$8,426 |
| 2018 |
$5,197 |
| 2017 |
$7,727 |
| 2016 |
$7,884 |
| 2015 |
$6,645 |
| 2014 |
$2,369 |
| 2013 |
$5,332 |
| 2012 |
$5,725 |
| 2011 |
$3,668 |
| 2010 |
$4,836 |
| 2009 |
$5,950 |
AbbVie Quarterly Pre-Tax Income
(Millions of US $) |
| 2024-12-31 |
$-2,269 |
| 2024-09-30 |
$2,084 |
| 2024-06-30 |
$2,146 |
| 2024-03-31 |
$1,755 |
| 2023-12-31 |
$1,212 |
| 2023-09-30 |
$1,953 |
| 2023-06-30 |
$2,610 |
| 2023-03-31 |
$475 |
| 2022-12-31 |
$2,965 |
| 2022-09-30 |
$4,400 |
| 2022-06-30 |
$1,183 |
| 2022-03-31 |
$4,929 |
| 2021-12-31 |
$4,271 |
| 2021-09-30 |
$3,688 |
| 2021-06-30 |
$1,163 |
| 2021-03-31 |
$3,867 |
| 2020-12-31 |
$-1,507 |
| 2020-09-30 |
$2,500 |
| 2020-06-30 |
$-693 |
| 2020-03-31 |
$3,098 |
| 2019-12-31 |
$3,074 |
| 2019-09-30 |
$2,001 |
| 2019-06-30 |
$807 |
| 2019-03-31 |
$2,544 |
| 2018-12-31 |
$-2,373 |
| 2018-09-30 |
$2,761 |
| 2018-06-30 |
$2,012 |
| 2018-03-31 |
$2,797 |
| 2017-12-31 |
$1,193 |
| 2017-09-30 |
$2,095 |
| 2017-06-30 |
$2,353 |
| 2017-03-31 |
$2,086 |
| 2016-12-31 |
$1,998 |
| 2016-09-30 |
$2,014 |
| 2016-06-30 |
$2,096 |
| 2016-03-31 |
$1,776 |
| 2015-12-31 |
$1,924 |
| 2015-09-30 |
$1,647 |
| 2015-06-30 |
$1,678 |
| 2015-03-31 |
$1,396 |
| 2014-12-31 |
$-1,037 |
| 2014-09-30 |
$687 |
| 2014-06-30 |
$1,433 |
| 2014-03-31 |
$1,286 |
| 2013-12-31 |
$1,439 |
| 2013-09-30 |
$1,286 |
| 2013-06-30 |
$1,368 |
| 2013-03-31 |
$1,239 |
| 2012-12-31 |
$1,713 |
| 2012-09-30 |
$1,604 |
| 2012-06-30 |
$1,402 |
| 2012-03-31 |
$1,006 |
| 2011-12-31 |
$2,810 |
| 2011-09-30 |
$0 |
| 2011-06-30 |
$0 |
| 2011-03-31 |
$858 |
| 2010-12-31 |
|
| 2009-12-31 |
|
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Large Cap Pharmaceutical |
$360.274B |
$56.334B |
|
AbbVie has become one of the top-most pharma companies after it acquired Allergan. The deal has transformed AbbVie's portfolio by lowering its dependence on Humira, its flagship product. AbbVie has one of the most popular cancer drugs in its portfolio, Imbruvica and its newest immunology drugs Skyrizi and Rinvoq position it well for long-term growth. AbbVie came into existence after Abbott Laboratories divested its pharmaceutical division. AbbVie enjoys leadership positions in key therapeutic areas including immunology, hematologic oncology, neuroscience, aesthetics, eye care and womens' health. Humira is approved for several autoimmune diseases like rheumatoid arthritis, active psoriatic arthritis, active ankylosing spondylitis, Crohn's disease and others. Imbruvica became part of the company's portfolio following the Pharmacyclics acquisition. Other key drugs include Venclexta, Botox Cosmetic, Botox Therapeutics, Vraylar, Skyrizi and Rinvoq.
|
